Prostate phytotherapy

Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia a randomized international study of 1098 patients. Prostate 4 231-240, 1996. 

SR108 Lowe, P. C., and ]. C. Ku. Phytotherapy in treatment of benign prostatic hyperplasia a critical review. Urology 1996 48(1) 12-20. 

SR109 Odenthal, K. P. Phytotherapy of benign prostatic hyperplasia (BPH) with Cucurbita, Hypoxis, Pygeum, Urtica and Sabal serrulata (Serenoa repens). Phytother Res 1996 10 S141-S143. 

Carraro JC, Raynaud JP, Koch G, Chisholm GD, Di Silverio F, Teillac P, Da Silva FC, Cauquil J, Chopin DK, Hamdy FC, Hanus M, Hauri D, Kalinteris A, Marencak J, Perier A, Perrin P. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia a randomized international study of 1,098 patients. Prostate I996 29(4) 23 I K). 

Medicinal herbs, or phytotherapy, have been used extensively for benign prostatic hyperplasia in Europe and are being used more commonly in the U.S. Sales of herbal medicine reached 4 billion in the U.S. in 1998, and sales of saw palmetto extract for treatment of symptoms attributable to benign prostatic hyperplasia exceeded 20 million, making it the seventh most commonly purchased medicinal herbal preparation. 

Duvia et al. "Advances in the Phytotherapy of Prostatic Hypertrophy." The effectiveness and tolerability of saw palmetto extract was compared with pygeum (Prunus ajricanium) extract in 30 patients with prostatic adenomas. The saw palmetto was superior to the pygeum in reducing symptoms, and it was much better tolerated. The Serenoa did not produce any side effects, while the pygeum caused gastric upset in 13 percent of the patients. 

Lowe EC, Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia An update. Urology 1999 53 671-678. 

Surgical procedures often are used to reduce a large prostate mass, but there are early pharmacological treatments of BPH with an ai-adrenergic blocker, a 5a-reductase inhibitor, and phytotherapy. 

Yam, J., M. Kreuter, and J. Drewe. 200. Piper cubeba targets multiple aspects of the androgen-signaUing pathway. A potential phytotherapy against prostate cancer growth Planta Med. 74(l) 33-38. 

---